Planned integration of Samsung ARTIKTM services with the Philips Healthsuite Digital Platform broadens ecosystem of products and services available to care providers
Amsterdam, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Samsung Electronics Co. Ltd. today announced plans for a strategic partnership to connect Samsung’s ARTIK Smart IoT Platform to the Philips HealthSuite Digital Platform. This collaboration will ultimately allow the Samsung ARTIK ecosystem of connected devices to safely access and share information with Philips’ cloud platform. Healthcare application developers will be able to realize interoperable connected health solutions using integrated data sets and innovative HealthSuite services such as advanced health analytics.
“This collaboration will enable healthcare application developers to focus on the development of innovative applications rather than on the technical integration of devices,” said Dale Wiggins, General Manager Philips HealthSuite Digital Platform at Philips. “By strengthening our HealthSuite ecosystem with Samsung ARTIK, we will be taking another important step in breaking down the silos in today’s healthcare domain to create a trusted and seamless care experience for both consumers and care professionals.”
“This is an incredibly exciting time in healthcare, as the industry begins to harness the power of data to bring better care to consumers,” said James Stansberry, Senior Vice President and GM, ARTIK IoT, Samsung Electronics. “Samsung ARTIK-enabled devices and cloud services integrated with Philips HealthSuite can address the growing need for connected health platforms that can safely access, share, and analyze information, helping health systems and providers achieve their goal of delivering better care to consumers, from prevention and detection to diagnosis and treatment.”
Broad range of applications and services
Device manufacturers using Samsung’s ARTIK hardware or cloud services will be able to deliver new benefits to their customers with the broad range of applications and services provided by the Philips HealthSuite Digital Platform, including integration of devices and device data into Electronic Medical Records (EMR), Personal Health Records (PHR), and advanced health analytics. Healthcare application developers working with the Philips HealthSuite Digital Platform will be able to use data from devices connected to Samsung’s SmartThings Cloud to develop new, data-driven connected health solutions. In addition, they can leverage data from various sources and IoT solutions, like QualcommLife, Validic and Philips’ own HealthSuite IoT solution which is based on Amazon Web Services IoT. Next to this, devices built with ARTIK secure Systems-on-Modules (SOMs) will also be able to integrate with the HealthSuite Digital Platform.
Philips HealthSuite Digital Platform is an open, secure platform of services, capabilities, and tools designed to enable development of next-generation connected health and wellness and healthcare innovations. It provides a range of digital tools for application developers and solution providers enabling universal ‘Big Data’ management, predictive analytics and Artificial Intelligence in support of health management by consumers and care professionals. Samsung’s ARTIK Smart IoT Platform is an open, enterprise-grade, secure platform that provides integrated solutions, from hardware systems-on-modules to cloud services, to help companies get to market faster with secure, interoperable, and intelligent IoT products and services. With strong security and privacy protection from hardware to cloud, ARTIK is ideally suited for industries such as healthcare.
Philips selected by Partners HealthCare and Triad HealthCare Network to help reduce costs of at-risk patients
Programs aim to reduce costs of medication non-adherence and improve treatment plan compliance among high-risk populations and patients with mental illness
Amsterdam, the Netherlands and Las Vegas, Nev. – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced participation in two programs to help improve medication adherence rates among at-risk, high-cost patient populations. Leveraging the Philips Medication Adherence Solution (PMAS), Lynn Community Health Center (LCHC) of Lynn, Mass. will work with Partners Connected Health of Partners HealthCare  to implement a Philips connected in-home medication dispensing solution to help improve treatment plan compliance among patients with mental illness. Triad HealthCare Network of Greensboro, N.C. will also incorporate Philips medication dispensing device in a program designed to improve patient medication adherence among chronic disease patients within the Medicare Advantage population.
As health systems work to better manage high-risk, high-cost patient populations to deliver value-based care successfully, it is critical they have access to the right data with actionable insights. PMAS offers care providers data-driven insights to help optimize medication management and increase patient engagement. By partnering with spencer Health Solutions, Philips offers a connected ecosystem: a monitored in-home dispensing device, pre-packaged, unit-dose medications from mail order and specialty pharmacies, a clinician portal and a caregiver app. The advanced solution provides clinicians, pharmacists and caregivers with daily notifications of non-adherent patients, helping to facilitate delivery of proactive and preventive care, while driving down costs of medical complications related to non-adherence, such as unplanned hospital visits.
“Medication non-adherence costs the U.S. health system over $310 billion every year, and results in hundreds of thousands of preventable deaths annually.Philips data aggregation platforms provide continuous and seamless availability of data and their interpretation to help improve patient outcomes and financial results,” said Derek Ross, Business Leader of Population Health Management, Philips. “Participating in these programs with Partners Connected Health and Triad HealthCare Network helps our customers improve medication adherence of their highest-acuity patients, and to deliver better value-based care.”
“Patients on complex medication regimens are at a high-risk for being unable to take their medication as prescribed,” said Dr. Kamal Jethwani, Senior Director at Partners Connected Health. “We have used technology successfully in the past to help such patients manage their medications. This would be our first trial in patients with mental illness, and if successful, would open an exciting opportunity to manage these patients in more effective ways.”
“Barriers to optimal health outcomes for our most vulnerable patients remain extensive and persistent,” said Emily Johnson, LCHC’s Director of Community Outreach. “With this program and our partnership with Partners HealthCare and Philips, our goals are to improve medication adherence rates through connected technology, build a foundation of intensive and ongoing care coordination, and cut costs of unplanned hospital visits.”
“Medication non-adherence is a multibillion dollar problem,” said James Osborne, MD, FACP, Senior Medical Director for Population Health, Cone Health, Triad HealthCare Network. “Through this program, we hope to discover an effective method to give our complex patients with a history of non-adherence the ability to stay on track easily. In turn, we aim to reduce unnecessary emergency transports and hospitalizations, and more effectively manage the cost of care.”
Programs designed to help improve medication adherence
LCHC’s program, funded by the Mass Health Policy Commission, will specifically target patients enrolled in MassHealth Primary Care Clinician (PCC) plans who are over 20 years old with a primary diagnosis of schizophrenia, bipolar disorder or major depression. Inadequate medication adherence among this population is one of the main causes for LCHC’s inpatient admissions and emergency department visits. Patients with complex mental illness are often on intricate treatment regimens with five or more prescriptions, and the behavioral challenges associated with their illnesses contribute to the likelihood of uncoordinated care and medication non-adherence.
Through a multi-faceted approach of intensive care coordination, clinical pharmacy consultation and Philips connected in-home medication dispenser, LCHC’s study aims to demonstrate a reduction in overall healthcare utilization by 15 percent, home health utilization by 40 percent, and both acute inpatient and outpatient utilization by 10 percent by the end of November 2018. By focusing on the highest risk patients, LCHC projects a savings of $1.4 million by the completion of the program.
Separately, Triad HealthCare Network’s program aims to enroll patients covered under three leading Medicare Advantage Part D health plans, with the goal of improving medication adherence rates, and consequently, overall patient health. Patients within this particular population tend to be the highest utilizers of their health systems and often live with chronic conditions that require complex prescription regimens.
The success of Triad HealthCare Network’s pilot program will be determined by performance indicators such as reduced costs of care and increased rates of medication adherence. Insights generated from PMAS, along with refill histories and pharmacy claims data, will assist healthcare providers and insurers to design a streamlined approach in caring for large, at-risk populations enrolled in the Medicare Advantage Part D health plans.
Philips Population Health Management
PMAS is part of Philips’ Population Health Management portfolio, which aims to achieve the quadruple aim of healthcare – better clinical outcome, lower cost, improved patient and staff satisfaction – via integrated solutions that include analytics, remote patient management and virtual care programs, and connected devices to help provide high quality care and manage cost and utilization while improving outcomes and revenue. For more information on Philips full suite of integrated solutions, visit booth #3812 at the 2018 Annual HIMSS Conference & Exhibition taking place March 4-9 at the Sands Expo in Las Vegas, NV. For updates on Philips presence at HIMSS, follow @PhilipsLiveFrom and visit www.philips.com/himss.
 The project described is supported by an Innovation Investment Award from the Commonwealth of Massachusetts Health Policy Commission (HPC). The contents of this release are the sole responsibility of the authors and do not necessarily represent the views of the HPC.
 New England Health Care Institute (NEHI), 2009.
 National Council on Patient Information and Education. Accelerating Progress in Prescription Medicine Adherence: The Adherence Action Agenda. A National Action Plan to Address America’s “Other Drug Problem.” October 2013. http://bemedicinesmart.org
March 9, 2018
Philips showcases innovative cardiovascular care solutions at the 2018 American College of Cardiology conference
• Intelligent cardiovascular care solutions seamlessly connect data, technology and people across the care continuum
• New health economic results on the comparative cost effectiveness of using an iFR-guided strategy in the assessment of coronary blockages when compared to an FFR-guided strategy to be presented during ACC.18
Amsterdam, the Netherlands and Orlando, U.S. – At the 2018 American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18), Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, is showcasing cardiovascular care solutions that make the management of patients more efficient and effective. By designing intelligent technologies and services that help clinicians to deliver a consistent standard of care, optimize care pathways and integrate workflows, Philips is enabling better patient and population outcomes.
“As a leading innovator in cardiovascular care, we are committed to support care providers and their patients with integrated solutions to address their biggest challenges,” said Bert van Meurs, Business Leader, Image Guided Therapy. “By seamlessly connecting data, technology and people across the health continuum, we’re bridging the gap in patient flow before entrance to the hospital and after discharge, helping to reduce costs and achieve optimal outcomes for patients.”
At ACC.18 Philips will also announce the presentation of new one-year follow-up DEFINE FLAIR trial data on the comparative cost effectiveness of using an iFR-guided strategy in the assessment of coronary blockages when compared to an FFR-guided strategy. This is intended to build on the DEFINE FLAIR trial data announced during ACC.17 , which found that iFR-guided treatments offer a 10 percent reduction in procedural time versus FFR-guided treatments, while reducing patient discomfort by 90 percent. iFR technology is proprietary to Philips.
Philips’ image-guided therapy solutions comprise interventional imaging systems, smart devices, software and services that enable clinicians to decide, guide, treat and confirm the appropriate cardiac and peripheral vascular treatment. On-site at ACC.18 Philips is exhibiting a range of integrated solutions for interventional cardiovascular procedures, including:
• Azurion, Philips’ next generation image-guided therapy platform, which enables clinicians to easily and confidently perform a range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care.
• New instant wave-Free Ratio (iFR) technology, iFR Roadmap , exclusive to Philips' interventional labs, which enables physicians to navigate coronary arteries and corresponding iFR data in real time.
• Philips’ SyncVision iFR co-registration solution, which couples iFR physiology measurement pull-back results to the coronary angio, which can be utilized in the stenting process when lesions are more complex.
• EchoNavigator, which automatically fuses live 3D TEE and live X-ray in real time so you can intuitively guide your device in the 3D space more quickly.
At ACC.18 Philips is also showcasing the latest innovations from its TOMTEC portfolio of intelligent image analysis software for automation and quantification in cardiac ultrasound, alongside a range of advanced ultrasound solutions, including:
• EPIQ with HeartModel, featuring the X8-2t Live 3D transesophageal transducer, the next level of cardiac imaging for fast, easy, and accurate transesophageal echocardiography that enables clinicians to diagnose surgical pathology in real time.
• Affiniti, supporting X7-2t Live 3D TEE, to deliver greater confidence and expand access to 3D transesophageal imaging to a wider range of patients.
• Lumify, now with the addition of the S4-2 phased-array transducer and cardiac exam preset, to deliver exceptional cardiac imaging and triage on any compatible Android device.
At Philips, we create scalable and interoperable health information management solutions that seamlessly connect data, technology and people across the care continuum. At ACC.18 Philips is showcasing the latest Healthcare Informatics innovations, including:
• IntelliSpace Cardiovascular 3.1, Philips’ next-generation cardiovascular image and information management system. Designed to help streamline workflow and improve operational performance throughout the cardiovascular service line, the latest version features enhanced security and enterprise protocols, seamless access to Philips’ QLAB and TOMTEC software tools, and the addition of browser-based reporting of stress echocardiogram (stress echo) tests.
• IntelliSpace Portal 10, the latest edition of Philips’ comprehensive, advanced visualization and quantification platform, was recently named 2018 Category Leader in the Advanced Visualization category in the 2018 Best in KLAS: Software & Services report .
For more information on Philips' integrated cardiology solutions, visit Philip’s booth (#2811) at ACC.18 or visit the Philips event page. Follow the #ACC18 conversation on @PhilipsLiveFrom throughout the event.
 Davies JE, et al., DEFINE-FLAIR: A Multi- Centre, Prospective, International, Randomized, Blinded Comparison of Clinical Outcomes and Cost Efficiencies of iFR and FFR Decision-Making for Physiological Guided Coronary Revascularization. New England Journal of Medicine, epub March 18, 2017
 iFR Roadmap is not a standalone technology. It can only be purchased as part of the Dynamic Coronary Roadmap package.
 The complete report is available for download at http://www.klasresearch.com/